Prostate cancer incidence and mortality rates among white and black men

Epidemiology

Volumn 8, Issue 2, 1997, Pages 126-131

  Merrill, Ray M ^a,b   Brawley, Otis W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Applied Research Program   (United States)

Author keywords

age at diagnosis; incidence; mortality; prostate cancer; race; stage at diagnosis; time trends

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CAUCASIAN; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; UNITED STATES;

EID: 0031050516     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199703000-00001     Document Type: Article

References (36)

1. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1992 (Tables and Graphs). DHHS Pub. No. (NIH)96-2789. Bethesda, MD: National Cancer Institute, 1995.
2. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990;82:1624-1628.
3. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343:251-254.
4. Roush GC, Holford TR, Schymura MJ, White C. Cancer Risk and Incidence Trends: The Connecticut Perspective. Washington DC: Hemisphere, 1987; 279-293.
5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-552.
6. Lange PH. New information about prostate-specific antigen and the paradoxes of prostate cancer. JAMA 1995;273:336-337.
7. Gilland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev 1994;3: 105-111.
8. Danley KL, Richardson JL, Bernstein L, Langholz B, Ross RK. Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States). Cancer Causes Control 1995;6:492-498.
9. Hsing AW, Devesa SS. Prostate cancer mortality in the Unites States by cohort year of birth, 1865-1940. Cancer Epidemiol Biomarkers Prev 1994; 3:527-530.
10. Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG. Representativeness of the Surveillance, Epidemiology, and End results Program data: recent trends in cancer mortality rates. J Natl Cancer Inst 1992;84:872-877.
11. Chu KC, Miller BA, Feuer EJ, Hankey BF. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol 1994;47:1451-1461.
12. Chu KC, Horm JW, Smart CR. Estimating cancer mortality rates from SEER incidence and survival data. Public Health Rep 1990;105:36-46.
13. SEER Program: Comparative Staging Guide for Cancer: Major Sites: Colon and Rectum, Lung and Bronchus, Breast, Female Genital, Prostate Gland, Urinary Bladder. Bethesda, MD: National Institutes of Health, 1993.
14. Beahrs OH, Henson DE, Hutter RVP, Myers MH. Prostate. In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for Staging Cancer. 3rd ed. New York: JB Lippincott, 1988;177-182.
15. Frome EL. The analysis of rates using Poisson regression models. Biometrics 1983;39:665-674.
16. SAS Institute. SAS Technical Report P-243. SAS/STAT Software: The GENMOD Procedure. Release 6.09. Cary, NC: SAS Institute, 1993.
17. Hudson DJ. Fitting segmented curves whose join points have to be estimated. J Am Stat Assoc 1966;61:1097-1129.
18. Feuer EJ, Wun L. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol 1992;136:1423-1436.
19. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
20. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
21. Chodak GW. Screening for prostate cancer in 1993: is it appropriate or not? Semin Urol 1993;11:47-49.
22. Gerber GS, Chodak GW. Routine screening for cancer of the prostate. J Natl Cancer Inst 1991;83:329-335.
23. Morrison AS: Screening in Chronic Disease. New York: Oxford University Press, 1985.
24. Johansson JE, Anderson SO, Krusemo UB, Adami H-O, Bergstrom R, Kraaz W. Natural history of localized prostatic cancer. Lancet 1989;1:799-803.
25. Krahn M, Mahoney J, Eckman M, Trachtenberg J, Packer S, Deutsche A. Screening for prostate cancer: a decision analytic view. JAMA 1994;272: 773-780.
26. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-923.
27. Flemming C, Watson J, Albertsen P, Barry M, Wennberg J. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-2658.
28. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804-818.
29. Whitmore WF. Management of clinically localized prostatic cancer: an unresolved problem. JAMA 1993:2676-2677.
30. Moon TD, Brawer MK, Wilt TJ. Prostate intervention versus observation trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. Monogr Natl Cancer Inst 1995;19:69-71.
31. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1944;152:1817-1819.
32. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995;13:93-100.
33. Lu-Yao GL, McLerran D, Watson J, Wennberg JE. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 1993;269:2633-2636.
34. Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990;143:538-544.
35. Connelly RR, Campbell PC, Eisenberg H. Central registry of cancer cases in Connecticut. Public Health Rep 1968;83:386-390.
36. Gershman ST, Flannery JT, Barrett H, Nadel RK, Meigs JW. Development of the Connecticut Tumor Registry. Conn Med 1976;40:697-701.